Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SK-1401 (Sargramostim) Inhalation PK Study
NCT02840708Phase 1Completed
- Sponsor
- Niigata University Medical and Dental Hospital
- Start
- May 2016
- Primary completion
- Dec 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of sargramostim in pulmonary alveolar proteinosis (PAP) (3 arms), sponsored by Niigata University Medical and Dental Hospital. Primary endpoint: Serum level of Sargramostim at 24 hours. Started May 2016; status: completed.
02
Drugs
sargramostim
03
Conditions
pulmonary alveolar proteinosis (PAP)
Beyond the preview
Go deeper on NCT02840708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02840708.